RGT 61159
Alternative Names: RGT-61159Latest Information Update: 18 Jun 2025
At a glance
- Originator Rgenta Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-myb expression inhibitors; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Adenoid cystic carcinoma; Colorectal cancer
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 12 Jun 2025 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia released by Rgenta Therapeutics
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia released by Rgenta Therapeutics
- 25 Apr 2025 Rgenta Therapeutics plans a second phase I/II trial for Acute myeloid leukaemia and high risk Myelodysplastic syndromes in the second half of 2025